| MeSH term | MeSH ID | Detail |
|---|---|---|
| Scorpion Stings | D065008 | 1 associated lipids |
| Drug-Related Side Effects and Adverse Reactions | D064420 | 3 associated lipids |
| Retrognathia | D063173 | 1 associated lipids |
| End Stage Liver Disease | D058625 | 1 associated lipids |
| Candidiasis, Invasive | D058365 | 2 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Thrombotic Microangiopathies | D057049 | 1 associated lipids |
| Central Serous Chorioretinopathy | D056833 | 1 associated lipids |
| Leukoencephalopathies | D056784 | 3 associated lipids |
| Netherton Syndrome | D056770 | 1 associated lipids |
| Latent Tuberculosis | D055985 | 1 associated lipids |
| Invasive Pulmonary Aspergillosis | D055744 | 1 associated lipids |
| Keratosis, Actinic | D055623 | 3 associated lipids |
| Multiple Pulmonary Nodules | D055613 | 2 associated lipids |
| Pancreatitis, Graft | D055589 | 1 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Primary Graft Dysfunction | D055031 | 1 associated lipids |
| Idiopathic Interstitial Pneumonias | D054988 | 1 associated lipids |
| Dendritic Cell Sarcoma, Interdigitating | D054739 | 1 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Dysuria | D053159 | 1 associated lipids |
| Nocturia | D053158 | 1 associated lipids |
| Delayed Graft Function | D051799 | 2 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Lymphohistiocytosis, Hemophagocytic | D051359 | 1 associated lipids |
| Granulomatosis, Orofacial | D051261 | 2 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Dyslipidemias | D050171 | 7 associated lipids |
| Diabetes Complications | D048909 | 4 associated lipids |
| Hepatic Insufficiency | D048550 | 1 associated lipids |
| Colitis, Collagenous | D046729 | 1 associated lipids |
| Protoporphyria, Erythropoietic | D046351 | 1 associated lipids |
| Coproporphyria, Hereditary | D046349 | 1 associated lipids |
| Ileus | D045823 | 3 associated lipids |
| Intestinal Volvulus | D045822 | 1 associated lipids |
| Cholecystolithiasis | D041761 | 2 associated lipids |
| Mastocytosis, Cutaneous | D034701 | 1 associated lipids |
| Hypoalbuminemia | D034141 | 1 associated lipids |
| Hyperuricemia | D033461 | 4 associated lipids |
| Papillomavirus Infections | D030361 | 4 associated lipids |
| Denys-Drash Syndrome | D030321 | 1 associated lipids |
| Pulmonary Disease, Chronic Obstructive | D029424 | 16 associated lipids |
| Polyomavirus Infections | D027601 | 1 associated lipids |
| Coronary Stenosis | D023921 | 6 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Brachial Plexus Neuritis | D020968 | 2 associated lipids |
| Neuroaspergillosis | D020953 | 2 associated lipids |
| Hypoxia-Ischemia, Brain | D020925 | 22 associated lipids |
| Central Nervous System Viral Diseases | D020805 | 1 associated lipids |
| Intracranial Thrombosis | D020767 | 2 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Nervous System Autoimmune Disease, Experimental | D020721 | 3 associated lipids |
| Stroke | D020521 | 32 associated lipids |
| Brain Infarction | D020520 | 17 associated lipids |
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Paraneoplastic Syndromes, Nervous System | D020361 | 1 associated lipids |
| Hypertensive Encephalopathy | D020343 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Ventricular Remodeling | D020257 | 28 associated lipids |
| Infarction, Middle Cerebral Artery | D020244 | 35 associated lipids |
| Optic Nerve Injuries | D020221 | 4 associated lipids |
| Facial Nerve Injuries | D020220 | 1 associated lipids |
| Trauma, Nervous System | D020196 | 2 associated lipids |
| Nocturnal Myoclonus Syndrome | D020189 | 1 associated lipids |
| Sleep Apnea, Central | D020182 | 1 associated lipids |
| Citrullinemia | D020159 | 1 associated lipids |
| Hepatopulmonary Syndrome | D020065 | 1 associated lipids |
| Epstein-Barr Virus Infections | D020031 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Miller Fisher Syndrome | D019846 | 1 associated lipids |
| Hepatitis C, Chronic | D019698 | 12 associated lipids |
| Hepatitis B, Chronic | D019694 | 4 associated lipids |
| Hepatitis, Autoimmune | D019693 | 1 associated lipids |
| Neurodegenerative Diseases | D019636 | 32 associated lipids |
| Intracranial Hypertension | D019586 | 4 associated lipids |
| Dermatitis, Perioral | D019557 | 4 associated lipids |
| Pouchitis | D019449 | 3 associated lipids |
| Endotoxemia | D019446 | 27 associated lipids |
| Oral Ulcer | D019226 | 1 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Fasciitis, Necrotizing | D019115 | 1 associated lipids |
| Postoperative Hemorrhage | D019106 | 7 associated lipids |
| Multiple Endocrine Neoplasia Type 2a | D018813 | 1 associated lipids |
| Anemia, Iron-Deficiency | D018798 | 6 associated lipids |
| Encephalitis, Viral | D018792 | 3 associated lipids |
| Hypoplastic Left Heart Syndrome | D018636 | 1 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Lichen Sclerosus et Atrophicus | D018459 | 2 associated lipids |
| Vasculitis, Leukocytoclastic, Cutaneous | D018366 | 5 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Angiofibroma | D018322 | 2 associated lipids |
| Cervical Intraepithelial Neoplasia | D018290 | 1 associated lipids |
| Seminoma | D018239 | 2 associated lipids |
| Smooth Muscle Tumor | D018235 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schwartz JJ et al. | Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. | 2007 | Transplantation | pmid:17893604 |
| Yamagami S et al. | Mechanism of concordant corneal xenograft rejection in mice: synergistic effects of anti-leukocyte function-associated antigen-1 monoclonal antibody and FK506. | 1997 | Transplantation | pmid:9233699 |
| Ouyang J et al. | Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. | 2005 | Transplantation | pmid:15912108 |
| Neuhaus P et al. | Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. | 1995 | Transplantation | pmid:7530868 |
| Tzakis AG et al. | Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. | 2003 | Transplantation | pmid:12717207 |
| Villanueva G and Baldwin D | Rosiglitazone therapy of posttransplant diabetes mellitus. | 2005 | Transplantation | pmid:16340782 |
| Numakura K et al. | Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. | 2005 | Transplantation | pmid:16340785 |
| Ashokkumar C et al. | Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. | 2011 | Transplantation | pmid:21747326 |
| Kim CD et al. | Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. | 2010 | Transplantation | pmid:20842074 |
| Shield CF et al. | Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9422413 |
| Takeguchi N et al. | Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. | 1993 | Transplantation | pmid:7681229 |
| Demetris AJ et al. | Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. | 1992 | Transplantation | pmid:1374944 |
| Bundick RV et al. | FK506 as an agonist to induce inhibition of interleukin 2 production. | 1992 | Transplantation | pmid:1374947 |
| Casey MJ et al. | Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. | 2014 | Transplantation | pmid:24717218 |
| Kasahara M et al. | Living-related liver transplantation for type II citrullinemia using a graft from heterozygote donor. | 2001 | Transplantation | pmid:11211185 |
| Ovuworie CA et al. | Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. | 2001 | Transplantation | pmid:11685108 |
| Mourad G et al. | Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. | 2001 | Transplantation | pmid:11579299 |
| Manitpisitkul W et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. | 2009 | Transplantation | pmid:19584685 |
| Dominguez J et al. | Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. | 2000 | Transplantation | pmid:11063349 |
| Jiang H et al. | Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. | 2002 | Transplantation | pmid:12085006 |
| Nogueira JM et al. | A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. | 1999 | Transplantation | pmid:10096529 |
| Shapiro R et al. | Posttransplant diabetes in pediatric recipients on tacrolimus. | 1999 | Transplantation | pmid:10096540 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Merkle M et al. | The effect of sevelamer on tacrolimus target levels. | 2005 | Transplantation | pmid:16177649 |
| Cooper MH et al. | Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. | 1994 | Transplantation | pmid:7509089 |
| Lo A et al. | Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. | 2004 | Transplantation | pmid:15114090 |
| Shoker A et al. | Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. | 2000 | Transplantation | pmid:10949194 |
| Egawa H et al. | Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. | 1995 | Transplantation | pmid:7533958 |
| Wallia A et al. | Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. | 2010 | Transplantation | pmid:20098286 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
| Jacobson PA et al. | Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. | 2012 | Transplantation | pmid:22334041 |
| Schneeberger S et al. | Cytomegalovirus-related complications in human hand transplantation. | 2005 | Transplantation | pmid:16123716 |
| Qi S et al. | Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. | 2000 | Transplantation | pmid:10798741 |
| McDiarmid SV et al. | Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. | 1993 | Transplantation | pmid:7685933 |
| Borger P et al. | Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. | 2000 | Transplantation | pmid:10798763 |
| Ceulemans LJ et al. | Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. | 2015 | Transplantation | pmid:25695790 |
| Ochiai T et al. | Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | 1989 | Transplantation | pmid:2474209 |
| Kasahara M et al. | Role of HLA compatibility in pediatric living-related liver transplantation. | 2002 | Transplantation | pmid:12438966 |
| Hudnall SD | Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? | 2002 | Transplantation | pmid:12369583 |
| Fukushima D et al. | Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. | 2015 | Transplantation | pmid:24846306 |
| Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
| Chan L et al. | Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. | 2008 | Transplantation | pmid:18360262 |
| de Jonge H et al. | Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. | 2010 | Transplantation | pmid:20592652 |
| Puig I Marà JM et al. | Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. | 2000 | Transplantation | pmid:10919604 |
| Erickson LM et al. | Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. | 2003 | Transplantation | pmid:12923448 |
| Maluccio M et al. | Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. | 2003 | Transplantation | pmid:12923450 |
| Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
| Mendez R et al. | A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. | 2005 | Transplantation | pmid:16082323 |
| Wang HD et al. | Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. | 2018 | Transplantation | pmid:29298238 |